Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Perspective
What's the King review think it's doing?
Is the King review sending industry a message that disruptive reform of the PBS is anything but over despite MA's agreement with government?
Approvals Action
First threat to $63m pain drug
Sandoz's new generic competitor could make a serious hole in the drug that represents close to 40 per cent of Mundipharma's total PBS earnings.
Pipeline Monitor
FDA issues flood of approvals
The US regulatory body issued a number of approvals this week including a new combination use for Janssen's oncology med Darzalex and two ADHD meds.